Advisory Services Network’s Oruka Therapeutics ORKA Stock Holding History

Advisory Services Network’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$843K	Sell	8,860 -1,940	-18%	-$129K	0.01%	1105
2026 Q1	$530K	Buy	+10,800	New	+$375K	0.01%	1246

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Advisory Services Network's ORKA Position: Q2 2026 in Review

Advisory Services Network reduced its Oruka Therapeutics (ORKA) stake by 18% in Q2 2026, selling an estimated $129K and leaving 8,860 shares worth $843K. The position accounts for 0.01% of the portfolio, ranked #1105.

Advisory Services Network first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

Advisory Services Network held 8,860 shares of Oruka Therapeutics worth $843K as of Q2 2026.
Advisory Services Network sold 1,940 Oruka Therapeutics shares in Q2 2026, an estimated $129K.
Oruka Therapeutics made up 0.01% of Advisory Services Network's portfolio in Q2 2026, its #1105 holding.
Advisory Services Network first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.